BioXcel Therapeutics (BTAI)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.09 (-18.97%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of BioXcel Therapeutics (BTAI)
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Key Insights

Critical company metrics and information

  • Share Price

    $0.40

  • Market Cap

    $20.01 Million

  • Total Outstanding Shares

    49.63 Million Shares

  • Total Employees

    74

  • Dividend

    No dividend

  • IPO Date

    March 8, 2018

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    203-643-8060

  • Address

    555 long wharf drive, New haven, CT, 06511

  • Homepage

    https://www.bioxceltherapeutics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Financing Activities, Continuing$34.51 Million
Net Cash Flow, Continuing$-24.74 Million
Net Cash Flow From Investing Activities, Continuing$24.83 Million
Net Cash Flow From Operating Activities, Continuing$-84.08 Million
Net Cash Flow From Financing Activities$34.51 Million
Net Cash Flow From Operating Activities$-84.08 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Operating Income/Loss$-76.63 Million
Research and Development$34.47 Million
Preferred Stock Dividends And Other Adjustments$0.00
Gross Profit$251,000.00
Revenues$2.28 Million
Income/Loss From Continuing Operations Before Tax$-72.64 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Other Non-current Assets$548,000.00
Equity Attributable To Parent$-85.63 Million
Accounts Payable$14.89 Million
Current Liabilities$25.56 Million
Fixed Assets$552,000.00
Equity Attributable To Noncontrolling Interest$0.00

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.